Status:
RECRUITING
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
United States Department of Defense
Conditions:
Prostate Cancer
Eligibility:
MALE
40-76 years
Brief Summary
The overarching goal is to prospectively recruit men considering active surveillance for treatment in the MAGIC (MRI And GPS Informing Choices for prostate cancer treatment) Cohort to provide meaningf...
Detailed Description
Active surveillance (AS) avoids or delays prostate cancer (PCa) treatment side effects for survivors. Blacks and men of lower socioeconomic status (SES) under-utilize this monitoring approach. Previou...
Eligibility Criteria
Inclusion
- Participants must have NCCN very low to favorable intermediate risk prostate cancer.
- Participants must be diagnosed within 3 months prior to study enrollment.
- Participants must be male, age 40-76 years old.
- Participants must be willing to consider active surveillance for treatment.
Exclusion
- Participants with less than 10 years life expectancy.
- Participants unable to complete standardized surveys.
- Participants with no access to the rectum for a transrectal ultrasound.
- Participants with a contraindication to magnetic resonance imaging (MRI).
Key Trial Info
Start Date :
October 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
222 Patients enrolled
Trial Details
Trial ID
NCT05424783
Start Date
October 15 2022
End Date
December 31 2025
Last Update
June 20 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University
Chicago, Illinois, United States, 60611
2
University of Illinois at Chicago
Chicago, Illinois, United States, 60612